Online inquiry

IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10215MR)

This product GTTS-WQ10215MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets RHD gene. The antibody can be applied in prevention of feto-maternal allo-immunization in RhD- women research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001127691.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6007
UniProt ID Q02161
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10215MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5340MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ5361MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ5620MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ7218MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ2210MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ10729MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ9161MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ10919MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MABT5102A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW